Abstract P2-16-01: A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC)

Triple Negative ◽

Controlled Trial ◽

Weekly Paclitaxel ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

Locally Recurrent

OT3-01-11: A Randomized, Phase II Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating MetMAb and/or Bevacizumab in Combination with Weekly Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-11 ◽

2011 ◽

Author(s):

BR Daniel ◽

M Campone ◽

V Dieras ◽

T Ervin ◽

W Yu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Controlled Trial ◽

Weekly Paclitaxel ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs18-p2-08-19 ◽

2019 ◽

Author(s):

MJ Wongchenko ◽

M Oliveira ◽

C Saura ◽

P Nuciforo ◽

I Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)

10.1158/1538-7445.am2018-ct041 ◽

2018 ◽

Cited By ~ 2

Author(s):

Mafalda Oliveira ◽

Cristina Saura ◽

Isabel Calvo ◽

Jay Andersen ◽

José Luis Passos Coelho ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdv263 ◽

2015 ◽

Vol 26 (9) ◽

pp. 1904-1910 ◽

Cited By ~ 39

Author(s):

V. Diéras ◽

M. Campone ◽

D.A. Yardley ◽

G. Romieu ◽

V. Valero ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Controlled Trial ◽

Weekly Paclitaxel ◽

Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)

10.1158/1538-7445.am2019-4891 ◽

2019 ◽

Author(s):

Zhen Shi ◽

Steven J. Isakoff ◽

Cristina Saura ◽

Paolo Nuciforo ◽

Isabel Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Phase Ii ◽

Gene Expression Analysis ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)

10.1158/1538-7445.sabcs18-4891 ◽

2019 ◽

Author(s):

Zhen Shi ◽

Steven J. Isakoff ◽

Cristina Saura ◽

Paolo Nuciforo ◽

Isabel Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Phase Ii ◽

Gene Expression Analysis ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz177 ◽

2019 ◽

Vol 30 (8) ◽

pp. 1289-1297 ◽

Cited By ~ 20

Author(s):

M. Oliveira ◽

C. Saura ◽

P. Nuciforo ◽

I. Calvo ◽

J. Andersen ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz242.076 ◽

2019 ◽

Vol 30 ◽

pp. v138

Author(s):

A.H. Awada ◽

J. Cortés ◽

S. Slater ◽

I. Macpherson ◽

T. Csoszi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Locally Recurrent ◽

First Line Treatment

Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs20-pd1-11 ◽

2021 ◽

Author(s):

Peter Schmid ◽

Jacinta Abraham ◽

Stephen Chan ◽

Adrian Murray Brunt ◽

Gia Nemsadze ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

First Line ◽

Double Blind ◽

Double Blind Placebo

Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps110 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS110-TPS110 ◽

Cited By ~ 1

Author(s):

W. M. Sikov ◽

C. M. Perou ◽

M. Golshan ◽

D. Collyar ◽

D. A. Berry ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Weekly Paclitaxel ◽

Randomized Phase Ii ◽

Dose Dense